Preclinical Chimeric Antibody Chimeric Antigen Receptor T Cell Progress in Digestive System Cancers.

Abstract

Digestive system cancers, including hepatocellular carcinoma, colorectal and gastric tumors, are characterized by high rates of incidence and mortality. Digestive cancers are difficult to diagnose during the early stages, and the side effects of chemotherapy are often severe and may outweigh the therapeutic benefits. Chimeric antibody chimeric antigen receptor T cell (CAR-T) therapy, a novel immunotherapy, has achieved excellent results for the treatment of hematological tumors. However, CAR-T treatment of solid tumors has struggled due to a lack of target specificity, a difficult tumor microenvironment, and T cell homing. Despite the challenges, CAR-T treatment of digestive cancers is progressing. Combining CAR-T with other targets and/or modifying the CAR may represent the most promising approaches for future treatment of digestive cancers.

• Authors: Peng Lü, Songlin Qiu, Ye Pan, Feng Yu, Keping Chen
• Journal: Cancer biotherapy & radiopharmaceuticals (Cancer Biother Radiopharm) Vol. 36 Issue 4 Pg. 307-315 (May 2021) ISSN: 1557-8852 [Electronic] United States
• PMID: 33481647 (Publication Type: Journal Article)

Chemical References

• Receptors, Chimeric Antigen

Topics

• Digestive System Neoplasms (physiopathology)
• Humans
• Receptors, Chimeric Antigen (immunology)
• T-Lymphocytes (immunology)